Educating Patients About the Need to Wait for Biomarker Test Results

Video Library —June 8, 2021
Kammi Fox-Kay, MSN, RN, AOCNS, ONN-CG(T)
Thoracic Oncology Nurse Navigator
University of Chicago Medicine
Chicago, Illinois
Cathy Simmons, RN, BSN, ONN-CG(T)
Thoracic Oncology Navigator
Sarah Cannon Cancer Institute
Plano, Texas
Lauren Welch, MSN, NP-C, AOCNP
Nurse Practitioner
Tennessee Oncology
Nashville, TN
Lauren Welch, Kammi Fox-Kay, and Cathy Simmons discuss their approaches to educating patients on the importance of waiting for biomarker testing before starting therapy for non–small cell lung cancer (NSCLC) to individualize therapy with the treatment that is best suited for their cancer and to achieve the best outcomes.
Related Articles
Navigating Patients with Chronic Lymphocytic Leukemia: An interview with Nikki Barkett, BSN, RN, OCN, and Chelsea Passwater, DNP, RN, AGCNS-BC, OCN, of the AONN+ CLL CAPE Initiative
September 2022 Vol 13, No 9
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia. The American Cancer Society estimates over 20,000 new CLL cases and over 4000 attributed deaths in 2022.
Keeping Patients on Track Throughout the Unresectable Stage III Treatment Journey
Benjamin Levy, MD, Kim Rohan, ANP-BC, AOCN, Lauren Welch, MSN, NP-C, AOCNP, Claudia T. Miller, BSN, RN, OCN, ONN-CG, Rasheda Persinger, MSN, NP-C
Lung Cancer Education Resources
Helping to Support Optimal Care in Small Cell Lung Cancer
Benjamin Levy, MD, Holly Chitwood, Kim Rohan, ANP-BC, AOCN, Lauren Welch, MSN, NP-C, AOCNP, Claudia T. Miller, BSN, RN, OCN, ONN-CG
Lung Cancer Education Resources
Last modified: November 15, 2022

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State